Format

Send to

Choose Destination
Anticancer Res. 2014 Jul;34(7):3683-8.

Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy.

Author information

1
Medical Oncology Unit, National Cancer Institute "Giovanni Paolo II", Bari, Italy brunetti.ae@gmail.com.
2
Scientific Direction, National Cancer Institute "Giovanni Paolo II", Bari, Italy.
3
Medical Oncology Unit, National Cancer Institute "Giovanni Paolo II", Bari, Italy.
4
Department of Surgery, Sapienza University of Rome, Rome, Italy.
5
Medical Oncology Unit, S.G. Moscati Hospital, Taranto, Italy.

Abstract

BACKGROUND:

Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal cavity of young males. Its prognosis is dismal, with current treatment options including the combination of multi-agent chemotherapy, aggressive surgery, radiation therapy, and autologous stem cell transplantation. Hyperthermic intraperitoneal chemotherapy (HIPEC) may also be an option.

CASE REPORT:

Herein we report the administration of the marine-derived multi-target antineoplastic agent, trabectedin, in a patient with DSRCT, heavily pre-treated with conventional multi-agent chemotherapy, HIPEC, and surgery.

RESULTS:

The patient achieved a prolonged partial response and an extended period of stable disease with third-line trabectedin, following disease progression after conventional multi-agent chemotherapy, HIPEC, and surgery.

CONCLUSION:

Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease.

KEYWORDS:

Chemotherapy; desmoplastic small round cell tumour; multimodal therapy; trabectedin

PMID:
24982387
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center